The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BUZZ-U.S. Stocks on the Move-BlackBerry, AcelRx, Repros, Diamond Foods, Nike

Fri, 26th Sep 2014 12:35

(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)

U.S. stock index futures were inching higher on Friday aftermajor indexes suffered their biggest drop since July, ahead ofdata on economic growth and consumer optimism.

Dow Jones industrial average futures were up 0.25percent at 16,942, S&P 500 futures were up 0.19 percentat 1,965.25 and Nasdaq 100 futures were up 0.24 percentat 4,017.

** BLACKBERRY LTD, Thursday close $9.8, +1.73 pctpremarket

The Canadian smartphone maker said itssecond-quarter loss narrowed to $207 million from $965 million ayear earlier in early sign turnaround efforts may be working.Still, revenue fell nearly 42 percent to $916 million, missingthe average analyst estimate of $949.63 million.

** ACELRX PHARMACEUTICALS INC, Thursday close$6.72, -17.71 pct premarket

The U.S. FDA said it would take another six months to reviewa marketing application on the drugmaker's recently rejectedpain management device.

** REPROS THERAPEUTICS INC, Thursday close $8.96,+11.61 pct premarket

The drug developer said its experimental drug to treat lowtestosterone, Androxal, met the main goal of late-stage study.

The U.S FDA has granted the company a pre-drug approvalmeeting to discuss Androxal in the first half of November.

** DIAMOND FOODS INC, Thursday close $26.62, +5.18pct premarket

The packaged food company reported better-than-expectedquarterly adjusted profit and sales, helped by higher demand forsnacks such as Pop Secret popcorn and Kettle potato chips.

** MICRON TECHNOLOGY INC, Thursday close $31.7, +6.91pct premarket

The memory chipmaker posted fiscal fourth-quarter resultsand gave a revenue outlook that impressed Wall Street as signsof stabilization in the personal computer industry supporteddemand for DRAM chips.

At least ten brokerages including Stifel Nicolaus andRaymond James raised their price targets on the stock.

** NIKE INC, Thursday close $79.75, +7.57 pctpremarket

The world's largest sportswear maker reported abetter-than-expected quarterly profit as it gains market sharein Europe and focuses on higher-margin products such as Flyknitsoccer boots.

Janney Capital Markets upgraded the stock to "buy" from"neutral" and at least 13 brokerages raised their price target.

** FINISH LINE INC, Thursday close $29.41, -10.06pct premarket

The footwear retailer posted a quarterly profit that missedWall Street's estimate, hurt by lower demand for basketballsporting goods. Its merchandise inventory increases 11.5percent.

** ALIBABA GROUP HOLDING LTD, Thursday close$88.92, +0.90 pct premarket

The newest way to bet on the fortunes of Chinese e-commerceheavyweight Alibaba will debut on Monday when its stock optionsgo live for trading, and investors should look for the initialaction to be very busy, but also choppy and potentially pricey.Options market traders say Alibaba puts and calls will likelysee heavy demand given the interest shown so far in the stocksince its record-setting $25 billion IPO last week.

** INTEL CORP Thursday close $34.14, +0.76 pctpremarket

Intel said it will pay as much as $1.5 billion for a 20percent stake in two mobile chipmakers with ties to the Chinesegovernment, in the hopes of catching up in a smartphone chipindustry dominated by rival Qualcomm Inc.

** APPLE INC, Thursday close $97.87, +0.92 pctpremarket

Apple broke its silence on complaints about bending iPhones,hours after withdrawing a glitch-ridden software update as thecompany struggles to restore momentum to the rollout of itslatest phones.

** ASTRAZENECA, Thursday close $70.99, +1.25 pctpremarket

The British pharmaceutical company said an expandeduse of its IRESSA treatment for lung cancer has been recommendedfor approval by European regulators. (Compiled by Shailaja Sharma in Bangalore; Editing by SavioD'Souza)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.